{"id":1536,"date":"2020-07-08T14:29:36","date_gmt":"2020-07-08T18:29:36","guid":{"rendered":"https:\/\/cutheme.local\/ips\/?p=1536"},"modified":"2026-03-17T12:44:32","modified_gmt":"2026-03-17T16:44:32","slug":"aptamers-as-a-therapeutic-tool-to-prevent-protein-aggregation-in-neurodegenerative-disease","status":"publish","type":"post","link":"https:\/\/research.carleton.ca\/ips\/2020\/aptamers-as-a-therapeutic-tool-to-prevent-protein-aggregation-in-neurodegenerative-disease\/","title":{"rendered":"Aptamers as a Therapeutic Tool to Prevent Protein Aggregation in Neurodegenerative Disease"},"content":{"rendered":"\n
\n
\n\n
\n
\n
\n

\n Aptamers as a Therapeutic Tool to Prevent Protein Aggregation in Neurodegenerative Disease\n <\/h1>\n \n \n <\/header>\n\n <\/div>\n\n <\/div>\n\n <\/div>\n<\/section>\n\n

We have discovered DNA aptamer sequences that bind to different alpha-synuclein morphologies. Notably, we have found one sequence that binds to alpha-synuclein monomers and inhibits the formation of larger oligomers and fibrils when tested in vitro. We have packaged this aptamer in a vehicle that was capable of crossing the blood brain barrier and tested its binding to alpha synuclein in a mouse model of Parkinson\u2019s disease. Using immunofluorescence, we were able to confirm both the delivery of the fluorescently labelled aptamer and that the aptamer co-localizes with an antibody specific for phosphorylated alpha synuclein monomer.<\/p>\n\n\n\n

PCT application number: PCT\/CA2018\/051335 (filed Oct. 22, 2018)<\/p>\n\n\n\n

International Publication Number: WO2019\/079887<\/p>\n\n\n\n

US application number: 16\/758,090 (filed Apr. 22, 2020)<\/p>\n\n\n\n

CA application number: 3079909 (filed Apr. 21, 2020)<\/p>\n\n\n\n

Inventor(s): DeRosa, Maria Cynthia; Holahan, Matthew Richard; McConnell, Erin Marie; Ventura, Katelyn Victoria; Callahan, Joshua Parker; Hunt, Vernon Harold Daniel<\/p>\n\n\n\n

Please contact Theresa White<\/a> for further information.<\/p>\n","protected":false},"excerpt":{"rendered":"

We have discovered DNA aptamer sequences that bind to different alpha-synuclein morphologies. Notably, we have found one sequence that binds to alpha-synuclein monomers and inhibits the formation of larger oligomers and fibrils when tested in vitro. We have packaged this aptamer in a vehicle that was capable of crossing the blood brain barrier and tested […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[26],"tags":[],"class_list":["post-1536","post","type-post","status-publish","format-standard","hentry","category-licensing-opportunities"],"acf":{"cu_post_thumbnail":""},"yoast_head":"\nAptamers as a Therapeutic Tool to Prevent Protein Aggregation in Neurodegenerative Disease - Industry and Partnership Services (IPS)<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/research.carleton.ca\/ips\/2020\/aptamers-as-a-therapeutic-tool-to-prevent-protein-aggregation-in-neurodegenerative-disease\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aptamers as a Therapeutic Tool to Prevent Protein Aggregation in Neurodegenerative Disease - Industry and Partnership Services (IPS)\" \/>\n<meta property=\"og:description\" content=\"We have discovered DNA aptamer sequences that bind to different alpha-synuclein morphologies. Notably, we have found one sequence that binds to alpha-synuclein monomers and inhibits the formation of larger oligomers and fibrils when tested in vitro. We have packaged this aptamer in a vehicle that was capable of crossing the blood brain barrier and tested […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/research.carleton.ca\/ips\/2020\/aptamers-as-a-therapeutic-tool-to-prevent-protein-aggregation-in-neurodegenerative-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"Industry and Partnership Services (IPS)\" \/>\n<meta property=\"article:published_time\" content=\"2020-07-08T18:29:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-17T16:44:32+00:00\" \/>\n<meta name=\"author\" content=\"cuthemeedtr5\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/research.carleton.ca\\\/ips\\\/2020\\\/aptamers-as-a-therapeutic-tool-to-prevent-protein-aggregation-in-neurodegenerative-disease\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/research.carleton.ca\\\/ips\\\/2020\\\/aptamers-as-a-therapeutic-tool-to-prevent-protein-aggregation-in-neurodegenerative-disease\\\/\"},\"author\":{\"name\":\"cuthemeedtr5\",\"@id\":\"https:\\\/\\\/research.carleton.ca\\\/ips\\\/#\\\/schema\\\/person\\\/70d1fd2e707f3121221e3f7b0a79ffa2\"},\"headline\":\"Aptamers as a Therapeutic Tool to Prevent Protein Aggregation in Neurodegenerative Disease\",\"datePublished\":\"2020-07-08T18:29:36+00:00\",\"dateModified\":\"2026-03-17T16:44:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/research.carleton.ca\\\/ips\\\/2020\\\/aptamers-as-a-therapeutic-tool-to-prevent-protein-aggregation-in-neurodegenerative-disease\\\/\"},\"wordCount\":159,\"articleSection\":[\"Licensing Opportunities\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/research.carleton.ca\\\/ips\\\/2020\\\/aptamers-as-a-therapeutic-tool-to-prevent-protein-aggregation-in-neurodegenerative-disease\\\/\",\"url\":\"https:\\\/\\\/research.carleton.ca\\\/ips\\\/2020\\\/aptamers-as-a-therapeutic-tool-to-prevent-protein-aggregation-in-neurodegenerative-disease\\\/\",\"name\":\"Aptamers as a Therapeutic Tool to Prevent Protein Aggregation in Neurodegenerative Disease - Industry and Partnership Services (IPS)\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/research.carleton.ca\\\/ips\\\/#website\"},\"datePublished\":\"2020-07-08T18:29:36+00:00\",\"dateModified\":\"2026-03-17T16:44:32+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/research.carleton.ca\\\/ips\\\/#\\\/schema\\\/person\\\/70d1fd2e707f3121221e3f7b0a79ffa2\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/research.carleton.ca\\\/ips\\\/2020\\\/aptamers-as-a-therapeutic-tool-to-prevent-protein-aggregation-in-neurodegenerative-disease\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/research.carleton.ca\\\/ips\\\/2020\\\/aptamers-as-a-therapeutic-tool-to-prevent-protein-aggregation-in-neurodegenerative-disease\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/research.carleton.ca\\\/ips\\\/2020\\\/aptamers-as-a-therapeutic-tool-to-prevent-protein-aggregation-in-neurodegenerative-disease\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/research.carleton.ca\\\/ips\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aptamers as a Therapeutic Tool to Prevent Protein Aggregation in Neurodegenerative Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/research.carleton.ca\\\/ips\\\/#website\",\"url\":\"https:\\\/\\\/research.carleton.ca\\\/ips\\\/\",\"name\":\"Industry and Partnership Services (IPS)\",\"description\":\"Carleton University\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/research.carleton.ca\\\/ips\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/research.carleton.ca\\\/ips\\\/#\\\/schema\\\/person\\\/70d1fd2e707f3121221e3f7b0a79ffa2\",\"name\":\"cuthemeedtr5\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d63a8a93c769877d413406fb8d1f029d55138736a47908162d9c533fca642e80?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d63a8a93c769877d413406fb8d1f029d55138736a47908162d9c533fca642e80?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d63a8a93c769877d413406fb8d1f029d55138736a47908162d9c533fca642e80?s=96&d=mm&r=g\",\"caption\":\"cuthemeedtr5\"},\"url\":\"https:\\\/\\\/research.carleton.ca\\\/ips\\\/author\\\/cuthemeedtr5\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aptamers as a Therapeutic Tool to Prevent Protein Aggregation in Neurodegenerative Disease - Industry and Partnership Services (IPS)","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/research.carleton.ca\/ips\/2020\/aptamers-as-a-therapeutic-tool-to-prevent-protein-aggregation-in-neurodegenerative-disease\/","og_locale":"en_US","og_type":"article","og_title":"Aptamers as a Therapeutic Tool to Prevent Protein Aggregation in Neurodegenerative Disease - Industry and Partnership Services (IPS)","og_description":"We have discovered DNA aptamer sequences that bind to different alpha-synuclein morphologies. Notably, we have found one sequence that binds to alpha-synuclein monomers and inhibits the formation of larger oligomers and fibrils when tested in vitro. We have packaged this aptamer in a vehicle that was capable of crossing the blood brain barrier and tested […]","og_url":"https:\/\/research.carleton.ca\/ips\/2020\/aptamers-as-a-therapeutic-tool-to-prevent-protein-aggregation-in-neurodegenerative-disease\/","og_site_name":"Industry and Partnership Services (IPS)","article_published_time":"2020-07-08T18:29:36+00:00","article_modified_time":"2026-03-17T16:44:32+00:00","author":"cuthemeedtr5","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/research.carleton.ca\/ips\/2020\/aptamers-as-a-therapeutic-tool-to-prevent-protein-aggregation-in-neurodegenerative-disease\/#article","isPartOf":{"@id":"https:\/\/research.carleton.ca\/ips\/2020\/aptamers-as-a-therapeutic-tool-to-prevent-protein-aggregation-in-neurodegenerative-disease\/"},"author":{"name":"cuthemeedtr5","@id":"https:\/\/research.carleton.ca\/ips\/#\/schema\/person\/70d1fd2e707f3121221e3f7b0a79ffa2"},"headline":"Aptamers as a Therapeutic Tool to Prevent Protein Aggregation in Neurodegenerative Disease","datePublished":"2020-07-08T18:29:36+00:00","dateModified":"2026-03-17T16:44:32+00:00","mainEntityOfPage":{"@id":"https:\/\/research.carleton.ca\/ips\/2020\/aptamers-as-a-therapeutic-tool-to-prevent-protein-aggregation-in-neurodegenerative-disease\/"},"wordCount":159,"articleSection":["Licensing Opportunities"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/research.carleton.ca\/ips\/2020\/aptamers-as-a-therapeutic-tool-to-prevent-protein-aggregation-in-neurodegenerative-disease\/","url":"https:\/\/research.carleton.ca\/ips\/2020\/aptamers-as-a-therapeutic-tool-to-prevent-protein-aggregation-in-neurodegenerative-disease\/","name":"Aptamers as a Therapeutic Tool to Prevent Protein Aggregation in Neurodegenerative Disease - Industry and Partnership Services (IPS)","isPartOf":{"@id":"https:\/\/research.carleton.ca\/ips\/#website"},"datePublished":"2020-07-08T18:29:36+00:00","dateModified":"2026-03-17T16:44:32+00:00","author":{"@id":"https:\/\/research.carleton.ca\/ips\/#\/schema\/person\/70d1fd2e707f3121221e3f7b0a79ffa2"},"breadcrumb":{"@id":"https:\/\/research.carleton.ca\/ips\/2020\/aptamers-as-a-therapeutic-tool-to-prevent-protein-aggregation-in-neurodegenerative-disease\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/research.carleton.ca\/ips\/2020\/aptamers-as-a-therapeutic-tool-to-prevent-protein-aggregation-in-neurodegenerative-disease\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/research.carleton.ca\/ips\/2020\/aptamers-as-a-therapeutic-tool-to-prevent-protein-aggregation-in-neurodegenerative-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/research.carleton.ca\/ips\/"},{"@type":"ListItem","position":2,"name":"Aptamers as a Therapeutic Tool to Prevent Protein Aggregation in Neurodegenerative Disease"}]},{"@type":"WebSite","@id":"https:\/\/research.carleton.ca\/ips\/#website","url":"https:\/\/research.carleton.ca\/ips\/","name":"Industry and Partnership Services (IPS)","description":"Carleton University","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/research.carleton.ca\/ips\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/research.carleton.ca\/ips\/#\/schema\/person\/70d1fd2e707f3121221e3f7b0a79ffa2","name":"cuthemeedtr5","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/d63a8a93c769877d413406fb8d1f029d55138736a47908162d9c533fca642e80?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/d63a8a93c769877d413406fb8d1f029d55138736a47908162d9c533fca642e80?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d63a8a93c769877d413406fb8d1f029d55138736a47908162d9c533fca642e80?s=96&d=mm&r=g","caption":"cuthemeedtr5"},"url":"https:\/\/research.carleton.ca\/ips\/author\/cuthemeedtr5\/"}]}},"_links":{"self":[{"href":"https:\/\/research.carleton.ca\/ips\/wp-json\/wp\/v2\/posts\/1536","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/research.carleton.ca\/ips\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/research.carleton.ca\/ips\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/research.carleton.ca\/ips\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/research.carleton.ca\/ips\/wp-json\/wp\/v2\/comments?post=1536"}],"version-history":[{"count":3,"href":"https:\/\/research.carleton.ca\/ips\/wp-json\/wp\/v2\/posts\/1536\/revisions"}],"predecessor-version":[{"id":1603,"href":"https:\/\/research.carleton.ca\/ips\/wp-json\/wp\/v2\/posts\/1536\/revisions\/1603"}],"wp:attachment":[{"href":"https:\/\/research.carleton.ca\/ips\/wp-json\/wp\/v2\/media?parent=1536"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/research.carleton.ca\/ips\/wp-json\/wp\/v2\/categories?post=1536"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/research.carleton.ca\/ips\/wp-json\/wp\/v2\/tags?post=1536"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}